Navigation Links
Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant
Date:3/5/2009

tic applications including wrinkles, acne scars, burns and periodontal disease. Isolagen also commercializes a scientifically-advanced line of skincare systems through its majority-owned subsidiary, Agera(R) Laboratories, Inc. For additional information, please visit www.isolagen.com.

Isolagen Forward Looking Statements

All statements in this news release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include, without limitation, FDA concurrence with the use of the Company's Evaluator Live Acne Scar Assessment scale, the Company's ability to complete, at a minimum, an additional Phase III study to complement study IT-A-008 in order to pursue FDA approval and licensure, the Company's ability to complete any financings or enter into any strategic partnerships, and the timely filing of the Biologics Licensing Application (BLA) with the FDA,. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, as updated in "Item 1A. Risk Factors" in the Company's Quarterly Reports on Form 10-Q. We operate in a highly competitive and
'/>"/>

SOURCE Isolagen, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
2. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Decision Resources Group ... the United States , 54 percent ... BRAF inhibitor Tafinlar for BRAF -mutation-positive unresectable ... have prescribed GlaxoSmithKline,s MEK inhibitor Mekinist. Among current ... (42 percent and 43 percent, respectively) expects to ...
(Date:9/18/2014)... 18, 2014  KIYATEC announced today that it ... Innovation Research (SBIR) Phase II Contract from the ... institutes and centers that comprise the National Institutes ... two year award, KIYATEC will expand its 3D ... the forefront of cancer therapy strategies: 1) cancer,s ...
(Date:9/18/2014)... MEETING, Pa. , Sept. 18, 2014 ... trial solutions, was recognized as the Disruptive ... for its ePharmaONE cloud-based eClinical platform. This ... and electronic trial master file (eTMF), a ... solution, and ePharmaSolutions, ReferralPlus+ patient screening and ...
Breaking Medicine Technology:At One Year Post-Launch, Approximately One Half of Surveyed U.S. Medical Oncologists Have Prescribed Single-Agent Tafinlar and Mekinist to Their Malignant Melanoma Patients 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 3
... 2011 Reportlinker.com announces that a new market ... Analytical Tool - Antibodies and Peptides ... "Analytical Tool – Antibodies and Peptides ... the vast amount of strategic possibilities that have ...
... 9, 2011 Reportlinker.com announces that a new ... Cetuximab - Comprehensive patent search ... Eliminate unnecessary risk with the industry benchmark ... is a regularly updated, professional patent search performed ...
Cached Medicine Technology:Reportlinker Adds Analytical Tool - Antibodies and Peptides in Oncology 2Reportlinker Adds Analytical Tool - Antibodies and Peptides in Oncology 3Reportlinker Adds Cetuximab - Comprehensive patent search 2Reportlinker Adds Cetuximab - Comprehensive patent search 3Reportlinker Adds Cetuximab - Comprehensive patent search 4
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, 2014 (HealthDay News) ... is starting to spread faster than ever, the World Health Organization ... viral infection were reported in just one week. That brings ... half of those reported in the past three weeks, the ... WHO has estimated that as many as 20,000 people could ...
(Date:9/18/2014)... Los Angeles, CA (PRWEB) September 18, 2014 ... manufacture and refine carbon dioxide, selling it to ... The largest markets for carbon dioxide are food and ... freeze products, such as fruits, vegetables or pizzas. The ... additive. Beverage manufacturers use the compound to carbonate soft ...
(Date:9/18/2014)... exercise is good for you. But new research from ... an added benefit for cancer patients undergoing chemotherapy. , ... found that combining exercise with chemotherapy shrunk tumors more ... professor in the School of Nursing and director of ... the senior author on the study, which appears in ...
(Date:9/18/2014)... WA (PRWEB) September 18, 2014 Qualis ... organizations, has published a white paper, “Advancing Primary ... of Health Information Technology.” , Authors Jeff Hummel, ... CCE provide guidance to organizations engaged in the work ... how health IT can bolster PCMH objectives, such as ...
(Date:9/18/2014)... one-day conference at the Milken Institute School of Public ... 2014 to discuss the Global Health Security Agenda (GHSA) ... this event is to invite discussion of proposed priorities ... action plans to curtail the current deadly Ebola outbreak. ... organizations and more than 50 countries have engaged in ...
Breaking Medicine News(10 mins):Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 2Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 3Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:Advancing Primary Care Through PCMH and HIT: New White Paper Connects the Dots 2Health News:Non-governmental stakeholders to discuss the Global Health Security Agenda 2
... Webinar: , , What: Coverity Webinar, ... 10 am PT, Where:, http://seminar2.techonline.com/registration/distrib.cgi?s=1346&d=2794 , ... the web at the, ... , Overview: , In this web seminar, ...
... Vista, LLC, a marketing,and information services firm focusing on ... Kevin Grossman, who has been with the company,for seven ... , In his new role, ... HRmarketer Services Group. Mr. Grossman will continue,to report ...
... DiseasePHOENIX, Feb. 12 Although major advances have been ... attention needs to be given to one of the ... -- the painful and often progressive condition called lymphedema, ... so much about cardiovascular disease, few physicians are familiar ...
... Md., Feb. 11 Dialysis Corporation of America (Nasdaq: ... fourth quarter and full year 2008 financial results on Thursday, ... company will also host a conference call in conjunction with ... following morning, Friday, March 6, 2009 at 10:00 AM EST. ...
... Study suggest streamlining of prescribing system to avoid ... -- Doctors often override electronic medication safety alerts ... prescribing drugs for patients, which suggests that physicians ... a U.S. study. , Researchers looked at ...
... Corporation (Nasdaq: RGEN ), a global leader ... today that the Company has received ISO 9001:2000 (ISO) ... and quality systems. ISO certification was granted for ... and related services underlying its Protein A business. ...
Cached Medicine News:Health News:Webinar Alert: Coverity Announces Verification and Validation of Medical Device Software with Static Analysis - A Review of FDA Guidance and Best Practices 2Health News:Kevin Grossman Named President of HRmarketer.com 2Health News:Vascular Experts Call for Increased Awareness of Growing Problem of Lymphedema 2Health News:Vascular Experts Call for Increased Awareness of Growing Problem of Lymphedema 3Health News:Dialysis Corporation of America Announces Fiscal Year 2008 Earnings Release Date 2Health News:Docs Override Most Electronic Drug Warnings 2Health News:Repligen Announces ISO 9001:2000 Certification 2Health News:Repligen Announces ISO 9001:2000 Certification 3
... Flexible biopsy forceps are extremely delicate ... incompetent repair source, they can easily be ... turn, damage your endoscopes. , On the ... flexible biopsy forceps can have a virtually ...
Mobile offers full life cycle service for Sp02 accessories that are the vital link between pulse oximeter and patient...
... With our factory-quality repairs, physicians know ... why more hospitals turn to Mobile Instrument ... We offer a full line of carbide ... our four-way quality control process. You'll enjoy ...
Inquire...
Medicine Products: